研究者詳細 - 佐治　重衡

論文 - 佐治　重衡

分割表示193 件中 81 - 100 件目／全件表示 >>

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition.

Uematsu T, Nakashima K, Kikuchi M, Kubota K, Suzuki A, Nakano S, Hirokaga K, Yamaguchi K, Saji S, Iwata H

Breast cancer (Tokyo, Japan) 28 ( 4 ) 983 - 984 2021年7月（ ISSN:1340-6868 ）

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.

Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T

Breast cancer (Tokyo, Japan) 28 ( 4 ) 985 - 986 2021年7月（ ISSN:1340-6868 ）

Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.

Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, Hanamura N, Yano K, Wada N, Saji S, Iwata H

Breast cancer (Tokyo, Japan) 28 ( 4 ) 989 2021年7月（ ISSN:1340-6868 ）

Chromosomal translocation t(11;14) and p53 deletion induced by the CRISPR/Cas9 system in normal B cell-derived iPS cells.

Azami Y, Tsuyama N, Abe Y, Sugai-Takahashi M, Kudo KI, Ota A, Sivasundaram K, Muramatsu M, Shigemura T, Sasatani M, Hashimoto Y, Saji S, Kamiya K, Hanamura I, Ikezoe T, Onodera M, Sakai A

Scientific reports 11 ( 1 ) 5216 2021年3月

Recommendations for the management of breast cancer patients during the COVID-19 pandemic from the Japan Breast Cancer Society.

Kawate T, Yoshida A, Sugae S, Asaga S, Kaise H, Saji S, Yamauchi C, Miyoshi Y, Yamauchi H, Ishikawa T

Breast cancer (Tokyo, Japan) 28 ( 2 ) 247 - 253 2021年3月（ ISSN:1340-6868 ）

日本乳癌学会によるCOVID-19パンデミック時の乳癌患者の診療に関する推奨事項(Recommendations for the management of breast cancer patients during the COVID-19 pandemic from the Japan Breast Cancer Society)

Kawate Takahiko, Yoshida Atsushi, Sugae Sadatoshi, Asaga Souta, Kaise Hiroshi, Saji Shigehira, Yamauchi Chikako, Miyoshi Yasuo, Yamauchi Hideko, Ishikawa Takashi, the Japan Breast Cancer Society

Breast Cancer 28 ( 2 ) 247 - 253 2021年3月（ ISSN:1340-6868 ）

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N·SAS-BC 01 trial and CUBC trial).

Ohno S, Saji S, Masuda N, Tsuda H, Akiyama F, Kurosumi M, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T, Ohashi Y

Breast cancer research and treatment 186 ( 1 ) 135 - 147 2021年2月（ ISSN:0167-6806 ）

Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan.

Sawaki M, Yamada A, Kumamaru H, Miyata H, Nakayama K, Shimizu C, Miyashita M, Honma N, Taira N, Saji S

Breast cancer 28 ( 1 ) 1 - 8 2021年1月（ ISSN:1340-6868 ）

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.

Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S

The Lancet. Oncology 22 ( 1 ) 74 - 84 2021年1月（ ISSN:1470-2045 ）

日本の高齢乳癌患者の臨床病理学的特徴、practical treatment、予後、臨床上の問題点(Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan)

Sawaki Masataka, Yamada Akimitsu, Kumamaru Hiraku, Miyata Hiroaki, Nakayama Kanako, Shimizu Chikako, Miyashita Mika, Honma Naoko, Taira Naruto, Saji Shigehira

Breast Cancer 28 ( 1 ) 1 - 8 2021年1月（ ISSN:1340-6868 ）

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N.

Lancet. 396 ( 10257 ) 1090 - 1100 2020年10月

Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab.

Natori Y, Sasaki E, Soeda S, Furukawa S, Azami Y, Tokuda E, Kanbayashi T, Saji S.

Journal for immunotherapy of cancer 8 ( 2 ) e001164 - e001164 2020年10月

談論　がんゲノム医療の現状について

佐治重衡

福島県病院協会会報 111 3 - 5 2020年6月

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).

Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S

Trials 21 ( 1 ) 391 2020年5月

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.

Breast Cancer. 27 ( 3 ) 322 - 331 2020年5月（ ISSN:1340-6868 ）

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S

Breast cancer (Tokyo, Japan) 27 ( 3 ) 389 - 398 2020年5月（ ISSN:1340-6868 ）

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

Park YH, Senkus-Konefka E, Im SA, Pentheroudakis G, Saji S, Gupta S, Iwata H, Mastura MY, Dent R, Lu YS, Yin Y, Smruti BK, Toyama T, Malwinder S, Lee SC, Tseng LM, Kim JH, Kim TY, Suh KJ, Cardoso F, Yoshino T, Douillard JY

Annals of oncology : official journal of the European Society for Medical Oncology 31 ( 4 ) 451 - 469 2020年4月（ ISSN:09237534 ）

Breast Cancer Provider Interval Length in Fukushima, Japan, After the 2011 Triple Disaster: A Long-Term Retrospective Study.

Ozaki A, Nomura S, Leppold C, Tsubokura M, Sawano T, Tsukada M, Morita T, Tanimoto T, Saji S, Kato S, Yamaoka K, Nakata Y, Ohira H

Clinical breast cancer 20 ( 2 ) e127 - e150 2020年4月（ ISSN:1526-8209 ）

Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer (CLEOPATRA): End-Of-Study Results From a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study

Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group

Lancet Oncol. 21 ( 4 ) 519 - 530 2020年4月

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.

Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 36 ( 6 ) 558 - 566 2020年2月（ ISSN:0732-183X ）

　前のページ - 次のページ　

<佐治 重衡>

論文 - 佐治 重衡

<佐治　重衡>

論文 - 佐治　重衡